



JUBILANT
LIFESCIENCES

September 29, 2016

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East,
Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

Sub: Issue of rated unsecured high yield bonds by our wholly-owned subsidiary, Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933 (the “US Securities Act”).

Further to our letter dated September 23, 2016, we would like to inform you that our material wholly-owned subsidiary, Jubilant Pharma Limited (“JPL”), has successfully completed the pricing of its rated unsecured high yield bonds (the “Notes”) at a yield of 4.875% per annum issued at par for US\$300 million maturing in September 2021. The issuer (JPL) has been rated **BB-** by Standard & Poor’s Ratings Services (“S&P”) and Fitch Inc. (“Fitch”) and the issue (the Notes) has been rated **BB-** by S&P and **BB** by Fitch.

The net proceeds of the Notes shall be used (a) to prepay the existing debts of JPL and its subsidiaries; (b) for upstreaming upto US\$50 million to Jubilant Life Sciences Limited for prepayment of its existing debts and (c) for general corporate purposes.

The above is for your information and records.

Thanking You,

Yours Sincerely,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624